Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | farnesyl diphosphate synthase | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Polyprenyl synthetase family protein | 0.0123843 | 0.5 | 0.5 |
Mycobacterium ulcerans | geranylgeranyl pyrophosphate synthase | 0.0123843 | 0.5 | 0.5 |
Trypanosoma cruzi | farnesyl pyrophosphate synthase, putative | 0.0123843 | 0.5 | 0.5 |
Echinococcus multilocularis | farnesyl pyrophosphate synthase | 0.0123843 | 0.5 | 0.5 |
Leishmania major | farnesyl pyrophosphate synthase | 0.0123843 | 0.5 | 0.5 |
Trichomonas vaginalis | geranylgeranyl pyrophosphate synthase, putative | 0.0123843 | 0.5 | 0.5 |
Trichomonas vaginalis | geranylgeranyl diphosphate synthase, putative | 0.0123843 | 0.5 | 0.5 |
Trypanosoma brucei | farnesyl pyrophosphate synthase | 0.0123843 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Probable geranylgeranyl pyrophosphate synthetase IdsA2 (ggppsase) (GGPP synthetase) (geranylgeranyl diphosphate synthase) | 0.0123843 | 0.5 | 0.5 |
Giardia lamblia | Farnesyl diphosphate synthase | 0.0123843 | 0.5 | 0.5 |
Schistosoma mansoni | farnesyl pyrophosphate synthase | 0.0123843 | 0.5 | 0.5 |
Toxoplasma gondii | polyprenyl synthetase superfamily protein | 0.0123843 | 0.5 | 0.5 |
Plasmodium falciparum | geranylgeranyl pyrophosphate synthase, putative | 0.0123843 | 0.5 | 0.5 |
Mycobacterium ulcerans | geranylgeranyl pyrophosphate synthase | 0.0123843 | 0.5 | 0.5 |
Trichomonas vaginalis | geranylgeranyl pyrophosphate synthase, putative | 0.0123843 | 0.5 | 0.5 |
Echinococcus granulosus | farnesyl pyrophosphate synthase | 0.0123843 | 0.5 | 0.5 |
Loa Loa (eye worm) | polyprenyl synthetase | 0.0123843 | 0.5 | 0.5 |
Plasmodium vivax | geranylgeranyl pyrophosphate synthase | 0.0123843 | 0.5 | 0.5 |
Trypanosoma cruzi | farnesyl pyrophosphate synthase | 0.0123843 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED50 (functional) | = 100 ug kg-1 | Effective dose in inhibiting osteoclastic bone resorption | ChEMBL. | 12825934 |
ED50 (functional) | = 100 ug kg-1 | Effective dose after subcutaneous administration to TPTX rats for 50% reduction of hypercalcemia | ChEMBL. | 12166945 |
ED50 (functional) | = 100 ug kg-1 | Effective dose in inhibiting osteoclastic bone resorption | ChEMBL. | 12825934 |
IC50 (functional) | = -6.46 | Negative logarithm of inhibitory concentration against bone resorption | ChEMBL. | 12825934 |
IC50 (binding) | = -5.73 | Inhibitory activity against farnesyl Pyrophosphate Synthase expressed as #NAME? (M) | ChEMBL. | 14613320 |
IC50 (binding) | = 1.9 uM | Inhibitory activity against farnesyl Pyrophosphate Synthase was determined | ChEMBL. | 14613320 |
IC50 (binding) | = 1.9 uM | Inhibitory activity against farnesyl Pyrophosphate Synthase was determined | ChEMBL. | 14613320 |
IC50 (functional) | = 5 uM | Antimicrobial activity against Plasmodium falciparum | ChEMBL. | 20185316 |
IC50 (functional) | = 30.92 uM | In vitro inhibitory concentration against the growth of Toxoplasma gondii in human foreskin fibroblast monolayer cells (HFF cells) | ChEMBL. | 15857119 |
IC50 (functional) | > 200 uM | In vitro growth inhibition against Entamoeba histolytica | ChEMBL. | 14695831 |
IC50 (functional) | > 200 uM | In vitro growth inhibition against Plasmodium falciparum | ChEMBL. | 14695831 |
IC50 (functional) | > 200 uM | In vitro growth inhibition against Entamoeba histolytica | ChEMBL. | 14695831 |
IC50 (functional) | > 200 uM | In vitro growth inhibition against Plasmodium falciparum | ChEMBL. | 14695831 |
IC50 (functional) | = 200 uM | Antimicrobial activity against Entamoeba histolytica | ChEMBL. | 20185316 |
Ki (binding) | = 0.18 uM | Binding affinity towards farnesyl Pyrophosphate Synthase using [14C]- isopentenyl pyrophosphate as radioligand | ChEMBL. | 14613320 |
Ki (binding) | = 0.18 uM | Binding affinity towards farnesyl Pyrophosphate Synthase using [14C]- isopentenyl pyrophosphate as radioligand | ChEMBL. | 14613320 |
LD50 (ADMET) | = 150 uM | Toxicity evaluated against human nasopharyngeal carcinoma KB cell line | ChEMBL. | 14695831 |
LD50 (ADMET) | = 150 uM | Toxicity evaluated against human nasopharyngeal carcinoma KB cell line | ChEMBL. | 14695831 |
Log IC50 (binding) | = 5.73 | Inhibitory activity against farnesyl Pyrophosphate Synthase expressed as #NAME? (M) | ChEMBL. | 14613320 |
Log IC50 (functional) | = 6.46 | Negative logarithm of inhibitory concentration against bone resorption | ChEMBL. | 12825934 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 | 20185316 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
4 literature references were collected for this gene.